Anfepramona [INN-Spanish] en es it fr

Anfepramona [INN-Spanish] Brand names, Anfepramona [INN-Spanish] Analogs

Anfepramona [INN-Spanish] Brand Names Mixture

  • No information avaliable

Anfepramona [INN-Spanish] Chemical_Formula


Anfepramona [INN-Spanish] RX_link

Anfepramona [INN-Spanish] fda sheet

Anfepramona_[INN-Spanish] FDA

Anfepramona [INN-Spanish] msds (material safety sheet)

Anfepramona_[INN-Spanish] MSDS

Anfepramona [INN-Spanish] Synthesis Reference

No information avaliable

Anfepramona [INN-Spanish] Molecular Weight

205.296 g/mol

Anfepramona [INN-Spanish] Melting Point

No information avaliable

Anfepramona [INN-Spanish] H2O Solubility

No information avaliable

Anfepramona [INN-Spanish] State

No information avaliable

Anfepramona [INN-Spanish] LogP


Anfepramona [INN-Spanish] Dosage Forms

25 mg tablets and 75 mg controlled-release tablets.

Anfepramona [INN-Spanish] Indication

Used in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction.

Anfepramona [INN-Spanish] Pharmacology

Diethylpropion is a sympathomimetic stimulant drug marketed as an appetite suppressant. Chemically, it is the N,N-diethyl analog of cathinone. Its mechanism of action is similar to other appetite suppressants such as sibutramine, phentermine and dextroamphetamine.

Anfepramona [INN-Spanish] Absorption

Diethylpropion is rapidly absorbed from the GI tract after oral administration.

Anfepramona [INN-Spanish] side effects and Toxicity

The reported oral LD50 for mice is 600 mg/kg, for rats is 250 mg/kg and for dogs is 225 mg/kg. Manifestation of acute overdosage include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, and panic states.

Anfepramona [INN-Spanish] Patient Information

No information avaliable

Anfepramona [INN-Spanish] Organisms Affected

Humans and other mammals